A novel human epidermal growth factor receptor-3 targeting antibody-drug conjugate for treatment of cancer

An Italian SME specialized in drug discovery has developed and patented a novel human epidermal growth factor receptor-3 (HER-3) targeting antibody-drug conjugate (ADC) for treating cancer. This molecule has shown potent therapeutic efficacy combined with a good safety profile.
The company is looking for pharmaceutical companies or investors for financial or license agreement to further develop the product in clinical trials. A research cooperation agreement is also foreseen.
ACTIS Cooperación Tecnológica
Enlace: A novel human epidermal growth factor receptor-3 targeting antibody-drug conjugate for treatment of cancer